NATEGLINIDE

Other

Brand names: Nateglinide

Oral

Mechanism of Action

12.1 Mechanism of Action Nateglinide lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets. Nateglinide interacts with the ATP-sensitive potassium (K + ATP ) channel on pancreatic beta-cells. The subsequent depolarization of the beta cell opens the calcium channel, producing calcium influx and insulin secretion. The extent of insulin release is glucose dependent and diminishes at low glucose levels. Nateglinide is highly tissue selective with low affinity for heart and skeletal muscle.

Indications

See full prescribing information

FDA Warnings

5 WARNINGS AND PRECAUTIONS Hypoglycemia: Nateglinide may cause hypoglycemia
Administer before meals to reduce the risk of hypoglycemia
Skip the scheduled dose of nateglinide if a meal is skipped to reduce the risk of hypoglycemia
1) Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide

Known Side Effects

8 documented side effects by frequency

Drug Not Working

1-10%

Diarrhea

1-10%

Shortness of Breath

1-10%

Fatigue

1-10%

Nausea

1-10%

Decreased Appetite

1-10%

Dizziness

1-10%

Vomiting

1-10%

Community Discussions

No community discussions found for NATEGLINIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Oral